MARKET

STOK

STOK

Stoke Therapeutics
NASDAQ
24.15
-0.59
-2.38%
After Hours: 24.15 0 0.00% 16:15 10/12 EDT
OPEN
24.65
PREV CLOSE
24.74
HIGH
24.67
LOW
24.10
VOLUME
372.98K
TURNOVER
--
52 WEEK HIGH
40.22
52 WEEK LOW
20.32
MARKET CAP
1.56B
P/E (TTM)
-7.1899
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and AbbVie (ABBV)
TipRanks · 7h ago
Stoke Therapeutics announces presentations of data for STK-002
TipRanks · 9h ago
Stoke Therapeutics Presents Data For STK-002 Supporting Disease-Modifying Potential In Autosomal Dominant Optic Atrophy At AAO 2026 Annual Meeting
Benzinga · 9h ago
Weekly Report: what happened at STOK last week (1005-1009)?
Weekly Report · 11h ago
How FDA Filing Clarity At Stoke Therapeutics (STOK) Has Changed Its Investment Story
Simply Wall St · 2d ago
Stoke Therapeutics (STOK) Could Be 46% Below Fair Value As Clinical Catalysts Build
Simply Wall St · 5d ago
Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Compugen (CGEN)
TipRanks · 6d ago
Stoke Therapeutics announces two presentations of data for STK-002 at AAO
TipRanks · 6d ago
More
About STOK
Stoke Therapeutics, Inc. is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with ribonucleic acid (RNA)-based medicines. The Company, through its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach, is engaged in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. TANGO aims to restore missing proteins by increasing or stoking protein output from healthy genes, thus compensating for the non-functioning copy of the gene. The Company is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. The Company’s initial focus is haploinsufficiency and diseases of the central nervous system and the eye.

Webull offers Stoke Therapeutics Inc stock information, including NASDAQ: STOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STOK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STOK stock methods without spending real money on the virtual paper trading platform.